The cord blood banking market is an interesting market, as its rate of growth has slowed over the past couple years. When the market is assessed by the number of cord blood units stored, cord tissue units banked, and number of units transplanted, there are regions that are experiencing growth and regions in decline. In particular, cord blood markets are experiencing strong growth within Asia, are relatively flat within North America, and are in decline within Europe. Additionally, cord blood banks within Europe have been some of the most proactive banks to expand into other areas of stem cell storage. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Actinium Receives Orphan Drug Designation From FDA for Iomab-B to Condition Patients for HSCT
In major news released today, Actinium Pharmaceuticals announced that the FDA has “granted orphan drug designation for Iomab-B, a radioimmuno-therapeutic that conditions relapsed and refractory Acute Myeloid Leukemia (AML) patients for a hematopoietic stem cell transplant (HSCT).”
The drug is key to condition patients undergoing a hematopoietic stem cell transplant, making it a significant announcement for the stem cell community.
To learn more, read the full press release below, printed with permission from Janet Vasquez, Managing Director/Founder of JV Public Relations NY and media contact for Actinium Pharmaceuticals, Inc. [Read more…]
Where is the Stem Cell Industry Headed? (We Interviewed 6 Executives to Find Out)
Without question, some of BioInformant’s most popular content has been our exclusive interviews with stem cell executives and key opinion leaders (KOL). Highlighted below are six of our most popular interviews. Enjoy! [Read more…]
Did You Hear About These Stem Cell Events?
The stem cell sector is fueled by innovation and rapid change. To keep you up-to-date, we recently released new coverage of the industry. Check it out and let us know what you think! [Read more…]
No Longer Just for Humans — Cord Blood Banking Now Available to Horses Too
VetiCell, LLC, has announced that it is launching a proactive stem cell storage program for animals, in which it will collect stem cells from the umbilical cord of horses or from the reproductive tissues of dogs following spay or neuter.
VetiCell is a sister company to AlphaCord, a human cord blood bank, with the two companies having the same owner and staff.
Currently, there are a couple companies operating in the veterinary stem cell market that collect stem cells through invasive methods (adipose or bone marrow). However, VetiCell’s new model is to collect veterinary stem cells without surgery from the umbilical cord of horses or from reproductive tissues after canine spay and neuter. These methods require no additional invasive surgery to collect an animal’s stem cells.
Since 2006, BioInformant has been tracking the human stem cell banking market. Initially, the market was focused on the storage of umbilical cord blood, although it has expanded over the past ten years to include the storage of other types of stem cells, including those present within cord tissue, dental pulp, adipose tissue, and more.
With hundreds of human cord blood banks now competing worldwide, it will be interesting to see whether any of them add equine cord blood banking to their portfolio of human stem cell storage services.
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- …
- 62
- Next Page »